Welcome to our dedicated page for Kymera Therapeutics SEC filings (Ticker: KYMR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biotechnology company focused on targeted protein degradation (TPD). Through these filings, investors can review how Kymera reports its clinical progress, collaboration agreements, financing activities and corporate governance matters.
Kymera’s current reports on Form 8-K disclose material events such as clinical data presentations for KT-621, an investigational first-in-class oral STAT6 degrader in atopic dermatitis and asthma, and updates on KT-579, an oral IRF5 degrader for immune-mediated diseases. 8-K filings also describe key collaboration developments, including the IRAK4 degrader KT-485/SAR447971 with Sanofi for immuno-inflammatory diseases and an exclusive option and license agreement with Gilead Sciences covering an oral CDK2 molecular glue degrader program for potential use in breast cancer and other solid tumors.
Filings related to public offerings and capital structure outline Kymera’s underwritten offerings of common stock and pre-funded warrants, shelf registration statements on Form S-3 and associated underwriting agreements and registration rights agreements. These documents explain how the company raises capital to advance its pipeline of preclinical and clinical degrader programs and may detail potential milestone and royalty structures under collaboration arrangements.
Users can also consult SEC filings for information on Nasdaq listing details, including the KYMR ticker on The Nasdaq Global Market, as well as shareholder meeting results, board composition and executive transitions. Stock Titan’s platform pairs these filings with AI-powered summaries that highlight key terms, material developments and financial implications, helping readers navigate complex documents such as 8-Ks, registration statements and related exhibits more efficiently.
Kymera Therapeutics, Inc. reported insider activity by its Chief Medical Officer, who filed a Form 4 for transactions in the company’s common stock on 12/08/2025.
The filing shows the officer exercised a stock option for 49,307 shares of common stock at an exercise price of $5.33 per share and, on the same date, sold common stock in multiple transactions with weighted average prices including $87.3711, $88.0215, $89.4264, $90.1226, $91.4639 and $92.19. These trades were effected under a Rule 10b5-1 trading plan dated June 2, 2025. After the transactions, the officer directly beneficially owned 109,992 shares of common stock and 34,083 stock options with a $5.33 exercise price.
Kymera Therapeutics, Inc. reported that it hosted a conference call on December 8, 2025 to discuss results from its BroADen Phase 1b atopic dermatitis patient trial of KT-621, described as a first-in-class, oral STAT6 degrader. The company furnished a related slide presentation as Exhibit 99.1, noting that this material is provided for informational purposes and is not deemed “filed” for liability under Section 18 of the Exchange Act or automatically incorporated into other securities filings. Kymera also stated it undertakes no obligation to update, supplement, or amend the slide materials.
Kymera Therapeutics (KYMR) filed its Q3 2025 10-Q, highlighting a strong liquidity position and ongoing collaboration-driven revenue. Cash, cash equivalents and marketable securities totaled $978.7 million as of September 30, 2025, supported by a June–July follow-on offering with approximately $288.4 million in aggregate gross proceeds. Total assets were $1.10 billion and stockholders’ equity was $946.3 million.
For Q3 2025, the company reported collaboration revenue of $2.764 million, research and development expense of $74.094 million, and a net loss of $82.175 million (basic and diluted net loss per share $0.94). Year-to-date through Q3, collaboration revenue was $36.341 million, net loss was $224.370 million, and cash used in operating activities was $166.144 million. Deferred revenue was $37.236 million, including $37.2 million from the $40.0 million upfront payment in the Gilead molecular glue degrader agreement, to be recognized over an estimated 1.5 years. Under the Sanofi IRAK4 collaboration, the company recognized $33.6 million year-to-date and remains eligible for up to $975 million in future milestones tied to development, regulatory and commercial events. As of October 31, 2025, common shares outstanding were 71,949,027.
Kymera Therapeutics (KYMR) reported insider transactions by its Chief Executive Officer on 10/29/2025 under a Rule 10b5-1 trading plan dated September 6, 2024. The CEO exercised 30,000 stock options at an exercise price of $2.08 per share and acquired 30,000 shares, then sold 30,000 shares in three trades at weighted average prices of $59.7225, $61.0186, and $61.4576.
The filing notes these sales occurred in multiple transactions within disclosed price ranges. Following the transactions, the reporting person held 660,482 shares of common stock directly. The stock option reported was fully vested and exercisable, and 405,559 derivative securities were beneficially owned following the transactions.
Kymera Therapeutics (KYMR) Form 4: The Chief Medical Officer reported transactions on 10/15/2025 under a Rule 10b5-1 trading plan dated June 2, 2025. He exercised 28,999 stock options at $1.31 and 22,210 options at $2.08, adding shares via option exercises.
He then sold 29,264 shares at a weighted average price of $60.37, 8,963 at $61.4929, 14,896 at $62.7233, and 6,453 at $63.0868. Following these transactions, he beneficially owned 109,992 shares directly.
Kymera Therapeutics (KYMR): insider transaction — The company’s Chief Medical Officer reported multiple trades on 10/13/2025. The officer exercised stock options for 800 shares at $1.31 and 673 shares at $2.08, then sold 3,114 shares at $60. Following these transactions, the officer directly owned 118,359 shares of common stock. The filing notes these trades were made under a Rule 10b5-1 trading plan dated June 2, 2025. The exercised options were fully vested and remain tied to grants expiring on 10/31/2028 and 05/22/2029.
Kymera Therapeutics (KYMR) director reported a Form 4 for Oct 13, 2025: exercised 5,000 stock options at $10.34 and sold 5,000 common shares at a $59.1898 weighted average price under a Rule 10b5-1 plan dated Sept 20, 2024.
Following these transactions, the filing shows 0 shares directly owned and 0 derivative securities remaining.
Bruce N. Jacobs, Chief Financial Officer of Kymera Therapeutics, reported multiple transactions under a Rule 10b5-1 trading plan adopted September 6, 2024. On 09/17/2025 he acquired 79,220 shares of Kymera common stock at $2.08 (via exercise of options) and sold 79,220 shares at a weighted-average price of $50.0048 (sales executed across prices $49.90–$50.25). After the transactions the filing reports 306,629 shares beneficially owned before the sale and 227,409 shares following the sale. The report discloses two stock option transactions with exercise price $2.08 that were fully vested and exercisable, and notes 523 shares were earlier acquired under the employee stock purchase plan on June 2, 2025.
Form 144 filed for Kymera Therapeutics, Inc. (KYMR) reporting a proposed sale of 79,220 shares of common stock through Morgan Stanley Smith Barney LLC on 09/17/2025. The filing shows the shares were acquired the same day by exercise of stock options from the issuer and were paid in cash. The aggregate market value of the shares at the proposed sale is reported as $3,864,351.60 and the company has 71,497,597 shares outstanding per the form. No other securities sales in the past three months are reported and the filer certifies they do not possess undisclosed material adverse information.
FAQ
What is the current stock price of Kymera Therapeutics (KYMR)?
What is the market cap of Kymera Therapeutics (KYMR)?
